Developing precision medicines by harnessing the power of protein isoforms
OUR APPROACH
Harnessing protein isoforms
Using a proprietary approach, we are identifying and developing precision therapies to harness the therapeutic potential of protein isoforms, with an initial focus on neuromuscular and neurological diseases. Combining cutting-edge research, state-of-the-art technologies, and a strong founding team with decades of experience in the field of cell and gene therapy, we are committed to developing innovative treatments that restore function and improve patient outcomes in these challenging disease areas.
WHO WE ARE
Our founders
Founded in 2023, we are an early stage, Oxford University spinout from Prof. Matthew Wood, Dr. Carlo Rinaldi, and Dr. Catheryn Lim’s research, currently based in Oxford, UK. Combining both academic and industry experience, our small but dedicated and passionate team are developing precision medicines for the treatment of serious diseases with significant unmet need.
Prof. Matthew Wood
CO-FOUNDER AND COMPANY DIRECTOR
- Professor of Neuroscience, Deputy Head of Medical Science Division, University of Oxford
- Over 20 years of experience in RNA biology and neuromuscular disease research, with a focus on developing RNA-based medicines, particularly advanced antisense oligonucleotides for Duchenne muscular dystrophy and related conditions. His work has pioneered novel drug delivery systems, including peptide and exosome-based technologies.
Dr. Carlo Rinaldi
CO-FOUNDER AND CONSULTANT
- Professor of Molecular and Translational Neuroscience, University of Oxford
- Honorary Consultant Neurology
- Over 15 years of experience in neurology and neuromuscular disease research, with expertise spans the study of genetic motor unit disorders, with a particular focus on spinal and bulbar muscular atrophy, as well as developing advanced therapeutic approaches for these conditions.
Dr. Catheryn Lim
CO-FOUNDER AND HEAD OF DISCOVERY
- Over 10 years of experience in gene regulation and therapeutic genomics. Her research focuses on understanding how dysregulation of transcription factor dynamics, gene isoforms and epigenetic regulation leads to disease. Her work has led to identification of novel genetic targets with therapeutic applications in neuromuscular diseases.
GET IN TOUCH
Contact us
If you are excited about the potential of isoform-based therapies to transform the lives of patients and would like to learn more about Isogenix, reach out!
Isogenix Limited
Bioescalator Innovation Building
Roosevelt Drive,
Oxford,
United Kingdom,
OX3 7FZ
